PMID- 30951818
OWN - NLM
STAT- MEDLINE
DCOM- 20190729
LR  - 20190729
IS  - 1096-1208 (Electronic)
IS  - 0882-4010 (Linking)
VI  - 131
DP  - 2019 Jun
TI  - Rhamnolipid-involved antibiotics combinations improve the eradication of 
      Helicobacter pylori biofilm in vitro: A comparison with conventional triple 
      therapy.
PG  - 112-119
LID - S0882-4010(19)30333-X [pii]
LID - 10.1016/j.micpath.2019.04.001 [doi]
AB  - Antibiotics resistance of H. pylori has been increasing constantly accompanied 
      with decreasing clearance rate clinically, which is demonstrated to be closely 
      related to biofilms with higher resistance than planktonic bacteria for the dense 
      extracellular polymeric substances. Rhamnolipid (RHL) is proved to not only 
      damage the structure of biofilm, but also potentially inhibit bacterial adhesion. 
      To investigate if RHL could promote eradicating rate of the conventional triple 
      therapy to H. pylori biofilm and hence attenuate the resistance and relapse of H. 
      pylori, first-line antibiotics clarithromycin (CLR), amoxicillin (AMX) or/and 
      proton pump inhibitor (PPI) involved single, dual or triple therapies were 
      compared with RHL-containing drug combinations on eradicating H. pylori biofilm. 
      The residual biofilm biomass, the survival of bacteria inside the remaining 
      biofilm and the planktonic bacteria dispersed from the biofilm after treatment 
      were tested. Combination with RHL significantly improved the ability of 
      antibiotics to eradicate H. pylori biofilm, especially RHL combined with AMX and 
      PPI could eradicate more than 95% of biofilm showing much more effective ability 
      than the conventional triple therapy CLR + AMX + PPI. Additionally, the 
      combination of RHL and antibiotics could effectively inhibit the biofilm 
      formation at lower concentration. Thus, RHL might be used as a potential 
      antibiotic adjuvant on anti-H. pylori therapy to enhance eradicating ability of 
      antibiotics to biofilms.
CI  - Copyright (c) 2019. Published by Elsevier Ltd.
FAU - Chen, Xiaonan
AU  - Chen X
AD  - Lab of Pharmaceutic, School of Pharmaceutical Sciences, Sun Yat-sen University, 
      Guangzhou, 510006, PR China. Electronic address: 405764607@qq.com.
FAU - Li, Pengyu
AU  - Li P
AD  - Lab of Pharmaceutic, School of Pharmaceutical Sciences, Sun Yat-sen University, 
      Guangzhou, 510006, PR China. Electronic address: 239938118@qq.com.
FAU - Shen, Yuanna
AU  - Shen Y
AD  - Lab of Pharmaceutic, School of Pharmaceutical Sciences, Sun Yat-sen University, 
      Guangzhou, 510006, PR China. Electronic address: 2258872734@qq.com.
FAU - Zou, Yiqing
AU  - Zou Y
AD  - Lab of Pharmaceutic, School of Pharmaceutical Sciences, Sun Yat-sen University, 
      Guangzhou, 510006, PR China. Electronic address: 386091617@qq.com.
FAU - Yuan, Gang
AU  - Yuan G
AD  - Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, 510080, PR China; Department of Geriatrics, The First 
      Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, PR China. 
      Electronic address: wongangzsu@163.com.
FAU - Hu, Haiyan
AU  - Hu H
AD  - Lab of Pharmaceutic, School of Pharmaceutical Sciences, Sun Yat-sen University, 
      Guangzhou, 510006, PR China. Electronic address: lsshhy@mail.sysu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20190402
PL  - England
TA  - Microb Pathog
JT  - Microbial pathogenesis
JID - 8606191
RN  - 0 (Glycolipids)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (rhamnolipid)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
MH  - Amoxicillin/pharmacology
MH  - Biofilms/*drug effects/growth & development
MH  - Clarithromycin/pharmacology
MH  - Drug Resistance, Bacterial
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Glycolipids/*pharmacology
MH  - Helicobacter pylori/*drug effects/growth & development
MH  - Microbial Sensitivity Tests
MH  - Microbial Viability/drug effects
MH  - Proton Pump Inhibitors/pharmacology
OTO - NOTNLM
OT  - Antibiotics combination
OT  - Biofilms
OT  - Eradication
OT  - Helicobacter pylori
OT  - Rhamnolipid
EDAT- 2019/04/06 06:00
MHDA- 2019/07/30 06:00
CRDT- 2019/04/06 06:00
PHST- 2019/02/23 00:00 [received]
PHST- 2019/03/29 00:00 [revised]
PHST- 2019/04/01 00:00 [accepted]
PHST- 2019/04/06 06:00 [pubmed]
PHST- 2019/07/30 06:00 [medline]
PHST- 2019/04/06 06:00 [entrez]
AID - S0882-4010(19)30333-X [pii]
AID - 10.1016/j.micpath.2019.04.001 [doi]
PST - ppublish
SO  - Microb Pathog. 2019 Jun;131:112-119. doi: 10.1016/j.micpath.2019.04.001. Epub 
      2019 Apr 2.